Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Approves Exforge for Hypertension | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

FDA Approves Exforge for Hypertension

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis received approval from the FDA for Exforge, a once-daily tablet combination of two high blood pressure medicines: Diovan, an angiotensin receptor blocker, and Norvasc, a calcium channel blocker.

The approval was supported by an extensive clinical program involving more than 5,000 patients. In two placebo-controlled trials, Exforge helped nine out of 10 patients reach their treatment goal of diastolic blood pressure under 90 mmHg, or more than a 10 mmHg reduction in diastolic blood pressure from baseline levels.

Exforge was approved in January 2007 in the EU and is currently available in nine EU countries, including Germany and the UK. Exforge is also available in Switzerland.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters